Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ANXA1 may influence hair growth in mice by regulating hair follicle stem cell proliferation through the EGF signaling pathway.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this study, researchers found that keratinocyte-specific deletion of the autophagy mediator Atg16l1 in mice heightened skin inflammation and cancer responses, altered hair follicle stem cell activity, and sensitized keratinocytes to cell death.

In this animal study, researchers observed that ginsenoside CK significantly reduced hair loss, improved sexual organ health, and encouraged hair growth in mice with androgenetic alopecia by modulating key signaling pathways and normalizing hormone metabolism, highlighting its potential as a therapeutic agent.

In this study, researchers identified KRT6A as a potentially important gene in mesenchymal stem cell-derived treatments for alopecia areata, revealing its role as a diagnostic marker, predictor of disease severity, and a protective factor, with overexpression alleviating hair loss in experimental models.

This study found that inhibiting AP-1 activity in mice modified tumor development, leading to transdifferentiation between squamous and sebaceous tumors, with molecular analysis suggesting AP-1's role in maintaining tumor cell identity.

JAK inhibitors are generally safe for treating alopecia areata.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This study found that in mice, perforin-mediated cytolysis by CD8 T cells is not necessary for the autoimmune attack on hair follicles in alopecia areata, suggesting other mechanisms are responsible for disease progression.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

This study developed a testosterone propionate-induced C57BL/6 mouse model of androgenetic alopecia, demonstrating that high-dose, prolonged testosterone administration inhibited hair regrowth and mirrored human AGA pathology, providing a useful platform for studying hair loss mechanisms and testing therapies targeting the Wnt/β-catenin pathway.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

This study developed an animal model that recreates alopecia areata by injecting healthy human skin grafts in immunocompromised mice with peripheral blood mononuclear cells enriched for NKG2D+ and CD56+ cells.

This study found that circAGK was highly expressed in AGA patients and promoted dermal papilla cell apoptosis, suggesting it as a potential target for treating androgen alopecia.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This study identified two single-nucleotide polymorphisms and three haplotypes in the KRTAP7-1 gene across yak, taurine, and zebu cattle, with the BOVIN-KRTAP7-1*A haplotype most prevalent.

Arg1+ macrophages may play a role in causing alopecia areata.

This study found that a non-scarring alopecia in C3H/HeJ mice resembles human alopecia areata and may serve as a valuable model for studying specific subtypes of the human condition.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This study found that AIRE, a usually nuclear protein, is expressed in the cytoplasm of human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin 17, potentially impacting ectodermal abnormalities in APECED syndrome.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

Alopecia areata involves complex immune cell interactions, especially between CD8+ T cells and macrophages, which could help develop new treatments.

This study found that botulinum toxin type A inhibited apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This study found that C3H mice with prior microbial exposure developed alopecia areata at a reduced rate and had fewer associated T cells compared to controls, suggesting that prior infections might attenuate autoimmune responses related to the disease.